OBJECTIVES: Exclusion of the left atrial appendage has been proposed to reduce the risk of stroke in patients with atrial fibrillation. The aim of this study was to evaluate the feasibility and efficacy of the AtriClip PROÁV device (AOD2), now in development, for left atrial appendage exclusion in a canine model.
INTRODUCTION
A variety of the left atrial appendage (LAA) surgical exclusion has been assessed mainly in observational studies and with mixed results [1] [2] [3] [4] . On the basis of the lessons from surgical closure, there has arisen a belief that elimination of the LAA as a source of systemic thromboembolism could be an effective alternative to pharmacological anticoagulation for patients with atrial fibrillation (AF). Alternative concepts to achieve LAA exclusion are obstruction of the LAA orifice with a surgical occlusion device [5] or percutaneous endocardial device [6, 7] and percutaneous suture ligation using an epicardial approach [8] .
We have reported on the continuing refinement of an atrial appendage exclusion device that has been developed through several design iterations for epicardial LAA exclusion on either a beating or an arrested heart [9] [10] [11] [12] . The early AtriClip device (AOD1; AtriCure, West Chester, OH, USA), which received approval from the US Food and Drug Administration in 2009 for LAA exclusion during open cardiac surgery, has been implanted in more than 50 000 cases worldwide [13] . With the AOD1, reliable and safe exclusion of the LAA has been demonstrated [14] . Two studies (on 34 and 71 patients undergoing cardiac surgery) reported complete occlusion rates of 100% and 98%, respectively, at 3 months, with no reported adverse events [5, 15] . Although there have been no problems with the AOD1, some surgeons prefer to approach the appendage from the side rather than from the top. Placing the clip from the side can be particularly helpful for some procedures, including minimally invasive cardiac surgery. The shape of the AOD1 has since been modified, resulting in the AtriClip PROÁV device (AOD2), to simplify placement. The purpose of the present study was to evaluate the AOD2 by epicardial echocardiography (EE), computed tomography (CT), gross pathology and histology in a canine model.
MATERIALS AND METHODS

Refined design of the AtriClip PROÁV device
The AOD1 now in clinical use consists of 2 titanium beams surrounded by a carbothane tube. A nitinol spring is inserted on each side of the clip into both beams. This spring applies an equal spring force on each end of the beam. Two tubes of knitbraided polyester fabric are slid over the beams and are sewn together at each end. The AOD1 opens to a rectangular shape and is applied to the base of the LAA by approaching it from the top (Fig. 1) . The AOD1 opens in parallel to 12 mm and then closes parallel to 0 mm. In contrast, the AOD2 is a single, continuous piece of titanium. The unique geometry acts as 2 springs and beams, applying equal pressure to both the proximal and the distal end of the beams. The geometry and way in which the clip is held by the applier causes the distal tips of the clip to close before the proximal tips of the beams. A single tube of knit-braided polyester fabric is draped around the clip and crimped into place at the tips of the beams, eliminating the need for sewing. The redesigned AOD2 opens to a 'V' shape and could be applied by approaching the LAA from the top or the side (Fig. 2) . The AOD2 opens in parallel to an opening of 4 mm. Opening beyond 4 mm is at an angle or 'V' shape. The AOD2 then closes with the distal tips first, down to 4 mm. At 4 mm, it closes parallel. So between 0 mm and 4 mm, the AOD2 closes in parallel to occlude the LAA, similar to the action of the AOD1.
A new raw material for the woven polyester knit fabric was sourced to find an alternative to the current material, which is becoming obsolete. The current and new material is woven by 2 different companies, but they each purchase the raw material from the same place. This 'new fabric' was included in this study as a way to further investigate the biocompatibility of the device and how well the new woven covering promoted tissue ingrowth for added stability of the AOD2 in situ. Six AOD2 devices covered with this new fabric were applied to the LAA (the intended location for clinical application), and 6 AOD1 devices (the current clinically used design) were applied to the right atrial appendage (RAA) as controls ( Table 1) . Four of these AOD1 devices were altered to employ the new fabric; the remaining 2 AOD1 devices were covered with the currently used fabric.
Study design
Six dogs (Coonhound, 23.6-29.0 kg) were used in the present study, which was approved by the Institutional Animal Care and Use Committee of the University of Minnesota.
The specific objectives of the study were to evaluate (i) safety, as assessed by physical observation of the test animal (morbidity and mortality); (ii) system performance at the initial surgery (delivery, placement and deployment of the AOD2 to the target atrial cardiac tissue), using a 5-point grading system (1-easy to 5-difficult); (iii) efficacy (complete appendage occlusion without device migration), as evaluated by CT, echocardiography, laboratory blood tests and adverse event information from the time of implant through study duration; (iv) biocompatibility of the test fabric (histopathology was used to examine the effects of the fabric on tissues at the site of AOD2 deployment and surrounding atrial areas); and (v) gross pathology for signs of thromboembolic 
: clinically available AtriClip device; AOD2: the AtriClip PRO V device; R: right atrial appendage; L: left atrial appendage.
events attributable to the test fabric. To allow enough time to complete these objectives, the animals were maintained with the implanted devices for 90 days or longer.
AtriClip device implantation
Each dog was sedated with acepromazine (0.04 mg/kg) intramuscularly. Anaesthesia was induced by administering propofol (2-6 mg/ kg) intravenously to effect. Each dog was placed in the right recumbent position. A left thoracotomy was performed through the fourth intercostal space. A fluid-filled catheter was inserted into the left internal mammary artery to monitor arterial blood pressure. The pericardium was opened parallel and anterior to the phrenic nerve. All procedures and measurements were performed on the beating heart condition. Two-dimensional epicardial echocardiography was used to assess the presence of any thrombus and continuation between the LAA and the left atrium (LA). The AOD2 devices were all implanted on the left. The AOD2 was applied from the side to the base of the LAA under direct visualization. Complete occlusion of the LAA was verified by epicardial echocardiography. Clip stability was also assessed. The right atrium (RA) was accessed by retracting the pulmonary artery (PA). The RAA was visualized in short intervals, allowing for relaxation on the PA so as not to compromise blood flow to the lungs. The AOD1 devices were implanted as shown in Table  1 . The AOD1 was applied to the base of the RAA under direct visualization. The same evaluations as for the LAA were performed. For both device designs, after confirmation of haemostasis, the chest was closed, with a chest drainage tube in place.
Postoperative care and data collection
All dogs were carefully monitored for at least 90 days. Postoperative analgesics and antibiotics were administered for 7-10 days after surgery; however, neither anticoagulation nor antiplatelet drugs were given during the postoperative period.
Blood samples were collected within 10 days prior to or on the day of the implant procedure and 4 days prior to or on the day of termination. The profile includes the following: complete blood cell count (white blood cell, differential, red blood cell, haemoglobin, haematocrit, free haemoglobin, fibrinogen, platelets and reticulocytes) and comprehensive metabolic panel (albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, amylase, anion gap, albumin/globulin, blood urea nitrogen, bicarbonate, calcium, cholesterol, chloride, creatinine, gamma-glutamyl transpeptidase, globulin, glucose, magnesium, potassium, sodium, osmolality, phosphorus, total protein, total bilirubin and triglycerides).
CT scans were scheduled to be performed prior to the implant, within 3 days following implant and within 5 days prior to termination.
Gross necropsy and histologic evaluation
At the completion of at least 90 days, heparin (300 U/kg, given intravenously) was administered, and the animals were humanely euthanized by intravenous injection of Beuthanasia D solution (87 mg/kg; Merck Animal Health, Madison, NJ, USA). Non-target tissues, including the brain, heart, lungs, spleen, kidneys and gastrointestinal tract, were evaluated for gross pathologic findings. Both AtriClip designs (AOD1 and AOD2) and surrounding structures were examined and photographed in situ. The heart with the affixed AtriClip, the trunk of the PA and the aorta (including the aortic arch and descending aorta) were removed en bloc. Photographs of the outer surfaces of the LAA and RAA were obtained. The PA was examined for any pinching or damage caused by the clip. Tissue growth into the clip fabric was assessed and photographed. Valves and chambers of the heart were dissected, with great care taken not to disrupt the lumen of the RAA or LAA, specifically the endothelial layers of the chambers. The endocardial lumens of the RAA and LAA were photographed to evaluate the presence of the endothelial layer and general condition of the lumen at both AtriClip sites. Observation was made in reference to closure of the atrial appendages and the presence or lack of fluid communication.
RESULTS
AtriClip device implantation and postoperative course
The ease of implantation of the AOD1 and AOD2 were deemed comparable, with the AOD2 scoring as 'easier to reach the target deployment area' in all 6 dogs ( Table 2 ). Once the LAA was exposed, the AOD2 was delivered to the LAA on the beating heart within approximately 1 min, without major complications or haemodynamic instability (Fig. 3A) . In all cases, epicardial echocardiography revealed no thrombus in the LAA and no communication between the LAA and LA after implantation. The AOD1 was successfully delivered to the RAA in all dogs (Fig. 3B) . In all cases, epicardial echocardiography revealed no thrombus and no communication between the RAA and RA after implantation. Fat tissue was pinched between the pull-bar and the loop of the applier in 3 of 6 AOD1 devices placed on the RAA; however, it was easily removed and did not affect the deployment procedure. There was no impingement of the PA, the clips were stable and there was no tearing or bleeding of the appendage. Occlusion of the RAA or LAA was confirmed for all clips via epicardial echocardiography.
All animals survived for the planned 90-day duration without complications, and their postoperative courses were uneventful. Results of blood samples (complete blood cell count and comprehensive metabolic panel) were unremarkable. 
Computed tomography
CT was performed at baseline (pre-surgery, post-surgery and just prior to euthanization to detect the presence of any thrombus, confirm the patency of the circumflex coronary artery, evaluate the structure of the LAA and RAA, verify the occlusion of the LAA and RAA and assess device migration. However, evaluation of CT images was hampered by a mishap; all post-surgery CT images were inadvertently deleted before being evaluated completely. Therefore, data for all animals at all time points were not available. At the time of baseline CT, no thrombus was found in the LA or RA or any other locations imaged, the circumflex arteries were patent and the LAA and RAA were not occluded. Post-implantation, based on the images that were evaluated, the first 3 animals had no indication of thrombus in the LA or the RA, and the circumflex artery was patent.
Gross necropsy
LAA and RAA were all judged to be fully occluded (from the LA and RA, respectively) following the use of either of the AtriClip designs (AOD1 or AOD2), with no evidence of device migration found. The occluded orifice of the LAA was covered with connective tissue (Fig. 4) . One sample in the AOD2 group had a focal fibrous adhesion of the AtriClip device to the lung; this was most likely due to the close proximity of the clip to pulmonary tissue, and the functional impact of this adhesion was judged not to be significant. There was no evidence of any thrombotic event in any animal from either group. No clinically significant gross abnormalities were noted during necropsy. With regard to gross necropsy findings, no differences were noted between AOD2 (test) and AOD1 (control) with old and new fabric.
Histologic evaluation
The AOD1 and AOD2 displayed similar foreign body reactions to the presence of the fabric, with moderate amounts of macrophages and multinucleated giant cells interspersed throughout the fabric (Fig. 5A) . Also, all AtriClip devices had similar amounts of fibrous tissue ingrowth into the fabric surrounding the clip ( Fig. 5B and C) . Both AtriClip devices appeared to work well, as the samples from the 3 treatment groups achieved full occlusion of the atrial appendage, and no evidence of clip migration was found. Multiple occurrences of clip adhesion to the aorta or PA by fibrous connective tissue were found in all AtriClips, except for 2 clips in the AOD1 with new fabric. None of the occurrences appeared to have a negative impact on the vessel or clip, as no disruption or erosion of the vessel wall was noted. The foreign body reaction, an expected finding, was localized to the fabric surrounding the clip and did not spread into the surrounding fibrous connective tissue; thus, the atrial clips in the 3 treatment groups demonstrated an acceptable biocompatibility response with no significant histological difference. The safety and efficacy of the AtriClip devices were similar for the 3 groups, with no discernible differences in function or biocompatibility between treatments.
DISCUSSION
The preclinical safety of the latest design of the AOD2 for LAA exclusion was demonstrated with regard to morbidity/mortality compared with the clinically available AOD1. The AOD1 and AOD2 clips, using different fabrics, were successfully deployed on the LAA or RAA with no adverse events or complications related to the test material. System performance (delivery, placement and deployment) of the AOD2 was comparable to that of the AOD1. No adverse clinical observations or changes in body condition scoring related to the test material were observed during the course of the study. No changes in clinical pathology parameters were considered clinically significant. Moreover, the AOD2 might be preferable for use in minimally invasive cardiac surgery with limited manipulation because it can be deployed not only from the top but also from the side. Efficacy of the devices (represented by evaluation of appendage occlusion via epicardial echocardiography), clinical pathology and adverse events were comparable for the AOD2 and AOD1. Regarding biocompatibility and healing with the fabrics as ascertained via histopathology, both AOD2 and AOD1 clips demonstrated an acceptable biocompatibility response, with an expected foreign body reaction found between the 3 treatment groups. The 3 groups showed similar amounts of fibrous tissue ingrowth into the fabric, with no discernible differences in function or biocompatibility. These findings are consistent with the report from the University of California canine study and from clinical case reports with the LARIAT V R device (SentreHEART, Inc., Redwood City, CA, USA), in which there was atrophy and fibrosis and complete endothelialization of the endocardial surface at the occlusion site [16, 17] . Both AtriClip designs achieved full occlusion of the LAA or RAA, and no evidence of clip migration was observed. There were no macroscopic or microscopic findings in any of the end organs examined that were determined to be related to the AOD2 or the AOD1.
Several potential alternative methods are being evaluated. One alternative for stroke prevention in AF patients is percutaneous exclusion of the LAA from the circulatory system. In March 2015, the US Food and Drug Administration approved the WATCHMAN TM LAA closure device (Boston Scientific Corp., Marlborough, MA, USA) for minimally invasive endocardial LAA closure after completion of 2 pivotal randomized trials designed to demonstrate safety and efficacy of the device in comparison with warfarin therapy [7, 18] . Boersma et al. [19] reported that the WATCHMAN TM device had a high success rate in complete LAA closure (successful deployed rate 98.5%) with low periprocedural risk, even in a population with a higher risk of stroke and bleeding and with multiple comorbidities. Wiebe et al. [20] reported that procedural success was achieved in 96.1% of patients. During a mean 3-year follow-up period, annual rates of transient ischaemic attack, stroke, intracranial haemorrhage and death were 0.7, 0.7, 1.1 and 3.5%, respectively. A novel technique for suture delivery has been developed to achieve LAA closure: the LARIAT V R device uses an endo-epicardial approach for epicardially ligating the LAA [21] . Pillarisetti et al. [22] demonstrated that the LARIAT V R device is associated with a lower rate of leaks at 1 year compared with the WATCHMAN TM device, with no difference in rates of cerebrovascular accident.
For the selection criteria of the method for the LAA closure, there are several things to be considered, including anatomic factors, prior surgical history, bleeding history and need for other interventions. Patients with prior cardiothoracic surgery are not good candidates for epicardial LARIAT closure. LARIAT closure may also be very difficult in patients with pectus excavatum, a superiorly directed LAA or an LAA that courses behind the PA. The width of the ostium, the length and shape of the LAA are also all very important to consider with endocardial approaches [23] . Unfortunately, there are no completed clinical trials comparing endocardial, epicardial and surgical devices including WATCHMAN and LARIAT. Also, the surgical LAA closure including thoracoscopic AtriClip is useful as a remedy for the failure of endocardial and epicardial devices [24] .
Limitations
There are limitations in this preclinical study of the 2 designs of the AtriClip. First, although canine LAA anatomy has many similarities to the human LAA, in several parameters, such as angulation and morphology, it does not precisely represent human AF. Second, the study number was small (n = 6), and the follow-up period was only 90 days. It is possible that there would be device failures and/or deployment complications with a longer followup or with application in patients, whose tissues are less elastic than those of the healthy canines used in our study. In addition, the experimental animals started out in sinus rhythm rather than AF. All post-surgery CT data were deleted, and as such they were not properly evaluated. Lastly, all the AOD1 devices were applied to the RAA, while all the AOD2 devices were applied to the LAA due to the limited number of AOD2 devices, which made direct comparison of the results difficult due to the anatomical and physiological differences.
CONCLUSION
In conclusion, the new AOD2 AtriClip for minimally invasive surgery achieved easy, reliable and safe exclusion of the LAA, with favourable histologic results, similar to the clinically available AOD1 AtriClip. Although further animal testing should include more detailed CT analysis and be done via a much less invasive procedure than in this study, clinical application could provide a new therapeutic option for lessening the risks of stroke in patients with AF.
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